GLP Done Right · India Intelligence · Feb 2026
GLP Drugs
India
CDSCO approved · live pricing in ₹ · patent cliff countdown Generic wave · what’s missing · independent clinical intelligence
🇮🇳
77M+ adults with T2D
265M+ overweight by 2025
Market: $110M → $150B+ by 2030
Patent cliff: March 2026
5
CDSCO Approved + Live
Actively prescribed in India
6+
Indian Generic Companies
Racing for March 2026 patent expiry
₹3K
Projected Generic Price
Post-March 2026 / 50–85% discount
29d
To Semaglutide Patent Expiry
March 31, 2026 — game changer
Semaglutide Patent Cliff — March 2026
Novo Nordisk’s secondary process/device patent expires in India in March 2026. This unlocks a major generic wave and will reshape access + pricing. Expect disruption across obesity care, supply chains, and prescribing patterns.
Semaglutide Patent Timeline — India
From Wegovy launch to generic flood
Jun 2025 Wegovy India launch
Feb 2026 ▲ You are here
Mar 2026 Patent expires 🔓
Mar 2025
Mounjaro launched — Eli Lilly. First GLP-1 dual agonist in India. Pricing varies by vial/pen. Partnerships accelerated distribution.
Jun 2025
Wegovy launched — Novo Nordisk. Premium pricing. Competes directly with Mounjaro.
Mar 2026
Semaglutide patent cliff — generic entry expected to change access and unit economics dramatically.
CDSCO Approved (Live)
Semaglutide
LIVE
Wegovy® / Rybelsus® · Novo Nordisk
GLP-1 · Weekly (inj) / Daily (oral)
High efficacy with strong appetite suppression. India access currently pricing-limited. Watch patent cliff dynamics.
💰 ₹17,000–25,000/mo (typical range)
📌 Live
Tirzepatide
LIVE
Mounjaro® · Eli Lilly
GLP-1 + GIP · Weekly
2nd gen dual agonist. Stronger weight loss than first gen for many profiles. Needs careful dosing + muscle protection.
💰 Varies by dose / supply
📌 Live
Pipeline (Expected / Watchlist)
Retatrutide
WATCH
Triple agonist · Lilly (global)
GLP-1 + GIP + Glucagon (investigational)
Likely a major efficacy step-up, but timelines + India filing unknown. Track trials and regulatory movement.
📌 No official India timeline
Missing in India
Mazdutide
MISSING
Xinermei® · Innovent/Lilly
🇨🇳 GCG/GLP-1 · China-approved
China-approved June 2025. ~20% weight loss reported. India plans not announced.
📌 India: No timeline yet
India Insight Box
Independent clinical + market intelligence for India.
Clinical Reality
Indian patients often respond strongly at lower dose ranges. Titration is critical and is frequently rushed.
Access Gap
Insurance coverage is near-zero for obesity drugs. Pricing keeps therapy out of reach for most patients without generics.
Counterfeit Risk
Grey market supply can include counterfeits. Cold chain + device authentication matter in supervised programs.
Market Trajectory
Fast growth + manufacturing capacity will be strategic. Generic entry changes volume even if price falls.
What to Ask Your Doctor
Ask about titration, symptom management, protein + muscle preservation, and metabolic monitoring beyond weight.
GLP-1 IN INDIA
Pricing and the generic race
A fast view of monthly maintenance costs and who’s closest to generic semaglutide.
PRICE COMPARISON
Price comparison — monthly cost (maintenance dose)
Monthly cost = 4 weekly doses. Pricing varies by pharmacy and city.
Mounjaro 15mg (max dose, KwikPen)
₹25,781 / mo
Wegovy 2.4mg (original price)
₹25,000 / mo
Mounjaro 2.5mg (starter dose)
₹13,125 / mo
Wegovy 2.4mgpost price cut
₹16,400 / mo
Wegovy 0.25mg (starting dose)post price cut
₹10,850 / mo
Ozempic 1mg
₹11,175 / mo
Ozempic 0.25mg starter
₹8,800 / mo
Generic semaglutide (projected, post-Mar 2026)
₹3,000–5,000 / mo
Monthly cost = 4 weekly doses. Prices are indicative and may vary by pharmacy and city. No insurance coverage for obesity indication in India (typical).
INDIAN PHARMA
Indian pharma — generic semaglutide race
Status, positioning, and projected price bands (indicative).
CompanyGeneric brand(s)IndicationUnique angleProjected priceStatus
Dr. Reddy’s Laboratories
TBA
T2D + Obesity
DCGI approved. Expected day-1 launch as patents open up.
₹3,000–5,000
✅ DCGI Approved (Jan 2026)
Alkem Laboratories
TBA
T2D + Obesity
DCGI approval in hand. Strong diabetes portfolio for access.
₹3,500–5,000
✅ DCGI Approved (Jan 2026)
Natco Pharma
TBA
T2D + Obesity
Filed non-infringement suit; seeking clarity pre-March 2026.
₹2,500–4,000
⚖️ Litigation / Preparing
Macleods Pharma
TBA
T2D + Obesity
Phase III BE trial protocol cleared; multiple strengths in pens.
₹3,000–4,500
🔬 Phase III Cleared
Intas Pharma
TBA
T2D
Multiple pen strengths; Phase III cleared Apr 2025.
₹3,000–4,000
🔬 Phase III Cleared
Cipla / Lupin / Biocon
Cipla: Yurpeak (tirzepatide, not sema)
Various
Cipla has tirzepatide distribution; others building peptide capability.
TBD
📋 Positioning
Tip: On mobile, swipe horizontally to view the full table.